N. O. Vlasenko
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
N. O. Vlasenko has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- N. M. Deviatkina
POLTAVA STATE MEDICAL UNIVERSITY, POLTAVA, UKRAINE
3 shared publications - Sergey Vladimirovich Kovalev
POLTAVA STATE MEDICAL UNIVERSITY, POLTAVA, UKRAINE
3 shared publications - Dmytro Karamyshev
POLTAVA STATE MEDICAL UNIVERSITY, POLTAVA, UKRAINE
2 shared publications - V. O. Korshenko
POLTAVA STATE MEDICAL UNIVERSITY, POLTAVA, UKRAINE
2 shared publications - Victoria I. Volochai
POLTAVA STATE MEDICAL UNIVERSITY, POLTAVA, UKRAINE
2 shared publications - A.R. Golovach
National University of Pharmacy, Kharkiv, Ukraine
1 shared publication
Latest Publications
- Open Access
- 30 September 2026
- Published by Poltava State Medical University (PSMU) in Ukrainian Dental Almanac
- No. 3,p. 5-11
RESEARCH AND ANALYSIS OF PHENOLIC COMPOUNDS IN ERIGERON ANNUUS FLOWERS FOR USE IN DENTISTRY
In the modern medical industry, there is a tendency to increase the share of herbal medicines in the global market of medicines, which is due to certain advantages of herbal medicines compared to synthetic ones. Herbal medicines are inferior to synthetic medicines in terms of effectiveness and potency, they are more economically advantageous, they are used for a long time, have low toxicity and almost have no side effects. Plants affect inflammation of the gums or oral mucosa, reduce toothache and are used for other pathologies of the oral cavity. When medicinal plants are used in dentistry, they exhibit the following therapeutic effects, such as antiseptic, antibacterial, antimicrobial, antiproliferative, antifungal, antioxidant, and antiviral, directly or indirectly.Flavonoids and phenolic acids constitute one of the most abundant groups of plant phenolic compounds. Due to the importance of the content of phenolic compounds for human and plant health, it is necessary to investigate the concentration of flavonoids and phenolic compounds to determine their potential as therapeutic agents and quality control of medicinal plants. Throughout life, a person consumes plants and herbs that contain thousands of flavonoid and phenolic acid components. The genus Erigeron, family Asteraceae, includes about 400 species. Erígeron ánnuus, (Phalacrolóma ánnuum) is an annual herbaceous plant, a species of the genus Small-petaled plant of the Compositae family. An invasive species originating from North America; was brought to Europe, where it spread very widely. HPLC-DAD determined the composition and content of flavonoids and hydroxycinnamic acids in the flowers of Erigeron annuus L. HPLC-DAD revealed 13 phenolic compounds, namely 5 flavonoids (rutin, neohesperidin, luteolin, naringenin, kaempferol) and 8 hydroxycinnamic acids (chlorogenic acid, syringic acid, benzoic acid, p-coumaric acid, trans-ferulic acid, sinapic acid, quinic acid, trans-cinnamic acid). The quantitative determination indicated that the main hydroxycinnamic acids are chlorogenic acid 1081.7 μg/g and sinapic acid 638,2 μg/g. neohesperidin 3433.64 μg/g, kaempferol 1713.88 μg/g, luteolin 1668.47 μg/g were the main flavonoids.
- 30 September 2026
- Published by Poltava State Medical University (PSMU) in Ukrainian Dental Almanac
- No. 3,p. 5-11
Open AccessRESEARCH AND ANALYSIS OF PHENOLIC COMPOUNDS IN ERIGERON ANNUUS FLOWERS FOR USE IN DENTISTRY
In the modern medical industry, there is a tendency to increase the share of herbal medicines in the global market of medicines, which is due to certain advantages of herbal medicines compared to synthetic ones. Herbal medicines are inferior to synthetic medicines in terms of effectiveness and potency, they are more economically advantageous, they are used for a long time, have low toxicity and almost have no side effects. Plants affect inflammation of the gums or oral mucosa, reduce toothache and are used for other pathologies of the oral cavity. When medicinal plants are used in dentistry, they exhibit the following therapeutic effects, such as antiseptic, antibacterial, antimicrobial, antiproliferative, antifungal, antioxidant, and antiviral, directly or indirectly.Flavonoids and phenolic acids constitute one of the most abundant groups of plant phenolic compounds. Due to the importance of the content of phenolic compounds for human and plant health, it is necessary to investigate the concentration of flavonoids and phenolic compounds to determine their potential as therapeutic agents and quality control of medicinal plants. Throughout life, a person consumes plants and herbs that contain thousands of flavonoid and phenolic acid components. The genus Erigeron, family Asteraceae, includes about 400 species. Erígeron ánnuus, (Phalacrolóma ánnuum) is an annual herbaceous plant, a species of the genus Small-petaled plant of the Compositae family. An invasive species originating from North America; was brought to Europe, where it spread very widely. HPLC-DAD determined the composition and content of flavonoids and hydroxycinnamic acids in the flowers of Erigeron annuus L. HPLC-DAD revealed 13 phenolic compounds, namely 5 flavonoids (rutin, neohesperidin, luteolin, naringenin, kaempferol) and 8 hydroxycinnamic acids (chlorogenic acid, syringic acid, benzoic acid, p-coumaric acid, trans-ferulic acid, sinapic acid, quinic acid, trans-cinnamic acid). The quantitative determination indicated that the main hydroxycinnamic acids are chlorogenic acid 1081.7 μg/g and sinapic acid 638,2 μg/g. neohesperidin 3433.64 μg/g, kaempferol 1713.88 μg/g, luteolin 1668.47 μg/g were the main flavonoids.
- Open Access
- 31 March 2026
- Published by National University of Pharmacy in News of Pharmacy
- Vol. 111 (1) , 43-48
Current trends in the standardization of the quality for phytochemical-directed medicinal products
The article discusses theoretical and practical aspects of standardization of medicinal products in pharmacy. The concept of standardization in pharmacy and its purpose, which is to ensure stable quality, safety and effectiveness of medicines, are considered. The importance of the regulatory framework in the process of standardization of medicinal products is emphasized. Examples of regulatory documents (Pharmacopoeias, state and international standards), such as the European Pharmacopoeia (Ph. Eur.)), the US Pharmacopeia (USP), the World Health Organization (WHO) Guidelines, are given. Aim. To determine and provide a comprehensive approach of the features of the drug standardization from the perspective of pharmacognosy, taking into account the principles of pharmacy and pharmacology. Materials and methods. The materials of the study were the publications of representatives of the domestic pharmacognostic doctrine and the works of foreign scientists. Regulatory documents at the level of the countries of the European Union, the USA, and the WHO have been analyzed. These documents include the European Pharmacopoeia (Ph. Eur.), Monograph 2034 “Herbal Drug Preparations”, the US Pharmacopeia (USP), three regulations (law-making acts) – the WHO Technical Report Series No.1010 (2018), the WHO Guidelines on Good Manufacturing Practices (GMP) for Herbal Medicines and the WHO Guidelines for assessing the quality of herbal medicines with reference to contaminants and residues, which are guiding for use in all member countries of the WHO. Results. The peculiarities of the drug standardization through the prism of the science of pharmacognosy, as well as related sciences, such as pharmaceuticals and pharmacology, have been determined. It has been found that current standardization trends involve the introduction of innovative technologies, in particular biotechnological methods, pharmacogenomics and artificial intelligence. It has been determined that the standardization of medicinal products can be called a multicomponent process, which differs depending on the boundaries (the WHO or a specific country and its pharmacopoeia) and the purpose of this process, but has as its ultimate goal the creation of uniform, transparent, open standards before obtaining a marketing authorization for a medicinal product, which takes place exclusively within the framework of the legal field. Conclusions. The standardization of medicinal products is a key process of pharmaceutical control that guarantees their quality, safety and effectiveness. It is based on international and national regulations, such as the European Pharmacopoeia, the US Pharmacopoeia and the WHO Guidelines. Improving standardization methods is the key to increasing the effectiveness and safety of medicines, which, in turn, contributes to improving the quality of medical care.
- 31 March 2026
- Published by National University of Pharmacy in News of Pharmacy
- Vol. 111 (1) , 43-48
Open AccessCurrent trends in the standardization of the quality for phytochemical-directed medicinal products
The article discusses theoretical and practical aspects of standardization of medicinal products in pharmacy. The concept of standardization in pharmacy and its purpose, which is to ensure stable quality, safety and effectiveness of medicines, are considered. The importance of the regulatory framework in the process of standardization of medicinal products is emphasized. Examples of regulatory documents (Pharmacopoeias, state and international standards), such as the European Pharmacopoeia (Ph. Eur.)), the US Pharmacopeia (USP), the World Health Organization (WHO) Guidelines, are given. Aim. To determine and provide a comprehensive approach of the features of the drug standardization from the perspective of pharmacognosy, taking into account the principles of pharmacy and pharmacology. Materials and methods. The materials of the study were the publications of representatives of the domestic pharmacognostic doctrine and the works of foreign scientists. Regulatory documents at the level of the countries of the European Union, the USA, and the WHO have been analyzed. These documents include the European Pharmacopoeia (Ph. Eur.), Monograph 2034 “Herbal Drug Preparations”, the US Pharmacopeia (USP), three regulations (law-making acts) – the WHO Technical Report Series No.1010 (2018), the WHO Guidelines on Good Manufacturing Practices (GMP) for Herbal Medicines and the WHO Guidelines for assessing the quality of herbal medicines with reference to contaminants and residues, which are guiding for use in all member countries of the WHO. Results. The peculiarities of the drug standardization through the prism of the science of pharmacognosy, as well as related sciences, such as pharmaceuticals and pharmacology, have been determined. It has been found that current standardization trends involve the introduction of innovative technologies, in particular biotechnological methods, pharmacogenomics and artificial intelligence. It has been determined that the standardization of medicinal products can be called a multicomponent process, which differs depending on the boundaries (the WHO or a specific country and its pharmacopoeia) and the purpose of this process, but has as its ultimate goal the creation of uniform, transparent, open standards before obtaining a marketing authorization for a medicinal product, which takes place exclusively within the framework of the legal field. Conclusions. The standardization of medicinal products is a key process of pharmaceutical control that guarantees their quality, safety and effectiveness. It is based on international and national regulations, such as the European Pharmacopoeia, the US Pharmacopoeia and the WHO Guidelines. Improving standardization methods is the key to increasing the effectiveness and safety of medicines, which, in turn, contributes to improving the quality of medical care.
- Open Access
- 4 November 2025
- Published by Poltava State Medical University (PSMU) in Актуальні проблеми сучасної медицини: Вісник Української медичної стоматологічної академії
- Vol. 25 (3) , 170-174
THE STATE OF ACID HEMOLYSIS OF ERYTHROCYTES UNDER EXTREME IMPACTS ON THE BODY AND ITS CORRECTION WITH AN ANTIOXIDANT
Introduction. Erythrocyte hemolysis accompanies certain diseases, increases under extreme impacts on the body, and may serve as a predictor of traumatic pathology or as an indicator of therapeutic efficacy and toxicity. Therefore, its study under different conditions remains relevant. Objective. To determine the features of acid hemolysis in laboratory animals under acute blood loss and acute immobilization stress, and to assess the effect of the antioxidant and stress-protector ethylmethylhydroxypyridine succinate. Materials and methods. Acute stress was induced by immobilizing rats on their backs for 3 hours. Acute blood loss was modeled by cardiac puncture with removal of 25% blood volume under anesthesia. Ethylmethylhydroxypyridine succinate (100 mg/kg) was administered intraperitoneally 30 minutes before immobilization or blood loss. Observations were conducted over 5 days. Acid resistance of erythrocytes was measured using the Terskov–Gitelzon method. Data were analyzed with Student’s t test and Fisher’s exact test. Results. In blood loss, hemolysis increased at baseline (3 h), time to maximum was shortened (24–72 h), maximum values decreased (3 h, 24 h, 5 d), and reaction duration was prolonged (3–72 h). With ethylmethylhydroxypyridine succinate, maximum time increased (3 h, 5 d) and reaction duration normalized (3 h). In immobilization stress, baseline hemolysis decreased at 5 d; maximum values exceeded control (3 h); reaction end time was prolonged; and final hemolysis increased (48 h, 5 d). With antioxidant treatment, onset decreased at 3 h, increased at 5 d, maximum exceeded pathology (3 h, 12 h), reaction time shortened, and final hemolysis decreased (48 h, 5 d). Conclusions. Extreme impacts alter erythrocyte acid hemolysis kinetics depending on stressor type and recovery stage. The effect of ethylmethylhydroxypyridine succinate is not uniformly protective, likely due to its combined antioxidant activity and regulatory influence on erythropoiesis.
- 4 November 2025
- Published by Poltava State Medical University (PSMU) in Актуальні проблеми сучасної медицини: Вісник Української медичної стоматологічної академії
- Vol. 25 (3) , 170-174
Open AccessTHE STATE OF ACID HEMOLYSIS OF ERYTHROCYTES UNDER EXTREME IMPACTS ON THE BODY AND ITS CORRECTION WITH AN ANTIOXIDANT
Introduction. Erythrocyte hemolysis accompanies certain diseases, increases under extreme impacts on the body, and may serve as a predictor of traumatic pathology or as an indicator of therapeutic efficacy and toxicity. Therefore, its study under different conditions remains relevant. Objective. To determine the features of acid hemolysis in laboratory animals under acute blood loss and acute immobilization stress, and to assess the effect of the antioxidant and stress-protector ethylmethylhydroxypyridine succinate. Materials and methods. Acute stress was induced by immobilizing rats on their backs for 3 hours. Acute blood loss was modeled by cardiac puncture with removal of 25% blood volume under anesthesia. Ethylmethylhydroxypyridine succinate (100 mg/kg) was administered intraperitoneally 30 minutes before immobilization or blood loss. Observations were conducted over 5 days. Acid resistance of erythrocytes was measured using the Terskov–Gitelzon method. Data were analyzed with Student’s t test and Fisher’s exact test. Results. In blood loss, hemolysis increased at baseline (3 h), time to maximum was shortened (24–72 h), maximum values decreased (3 h, 24 h, 5 d), and reaction duration was prolonged (3–72 h). With ethylmethylhydroxypyridine succinate, maximum time increased (3 h, 5 d) and reaction duration normalized (3 h). In immobilization stress, baseline hemolysis decreased at 5 d; maximum values exceeded control (3 h); reaction end time was prolonged; and final hemolysis increased (48 h, 5 d). With antioxidant treatment, onset decreased at 3 h, increased at 5 d, maximum exceeded pathology (3 h, 12 h), reaction time shortened, and final hemolysis decreased (48 h, 5 d). Conclusions. Extreme impacts alter erythrocyte acid hemolysis kinetics depending on stressor type and recovery stage. The effect of ethylmethylhydroxypyridine succinate is not uniformly protective, likely due to its combined antioxidant activity and regulatory influence on erythropoiesis.
- Open Access
- 29 September 2025
- Published by Dnipro State Medical University in Medicni perspektivi
- Vol. 30 (3) , 68-81
Oxidative stress in skin diseases and the role of antioxidants in their treatment
More and more preclinical and clinical studies indicate the crucial role of oxidative stress in the pathogenesis of skin diseases. This became the basis for the analysis of current literature data on oxidative stress and antioxidant protection in the skin in the norm and dermatological diseases, as well as on the antioxidants use to manage this pathology.The aim of the study was to review the current literature on oxidative stress and antioxidant protection in the skin and to analyze the possibilities of using antioxidants in skin diseases. The search for literature sources for 2005-2025 was carried out in the biometric search engine PubMed using the terms: “oxidative stress”, “antioxidant”, “skin”, “skin disease”, “topical treatment”, “α-tocopherol”, “ascorbic acid”, “polyphenol”, “quercetin”, “coenzyme Q10”, “resveratrol”, “N-acetylcysteine”, as well as word combinations based on them. The inclusion criteria were: a document in English; publication in the period 2005-2025; compliance with search queries; availability of the article full text. The exclusion criteria were: a case from practice; conference proceedings; a publication that does not meet the purpose of the review; lack of full text, reflection of skin manifestations of a systemic disease or infection. The maximum number of literature sources was found for the query “oxidative stress – antioxidant – skin” (n=3076). After systematizing the selected documents using bibliographic and analytical methods, 115 of the most relevant sources remained. It was shown that the suppliers of reactive oxygen species (ROS) in the skin are processes that occur in keratinocytes, fibroblasts, and hematogenous cells. Many antioxidants eliminate ROS in the skin, they act together with superoxide dismutase, catalase, glutathione peroxidase and non-enzymatic antioxidants. Disruption of the balance between ROS and the power of antioxidant protection, i.e. oxidative stress, accompanies contact dermatitis, urticaria, atopic dermatitis, psoriasis, malignant skin tumors, photoaging, and vitiligo. The contribution of key natural antioxidants (ascorbic acid, α-tocopherol, retinoids, coenzyme Q10, resveratrol, selenium, and polyphenols) to skin care has been described, but there was only a small number of evidence-based studies that would justify the dosage and indications for their use in dermatology. Synthetic antioxidants are represented by almost one N-acetylcysteine in the treatment of toxic epidermal necrolysis, drug hypersensitivity syndrome, ichthyosis, contact and atopic dermatitis and some other diseases. The topical use of antioxidants is complicated by the search for an adequate dosage form, in which the stabilization of a substance with antioxidant properties is crucial, as well as its absorption, the ability to reach the target tissue in an active form and remain there for a long enough time, which is solved by the use of new methods of drug delivery, in particular based on nanotechnology. Thus, changes in the redox balance are widely represented in dermatoses, and the use of antioxidants can be of great importance if they are prescribed rationally. Obviously, it is advisable to combine antioxidants with each other and to introduce synthetic antioxidants more widely into practice.
- 29 September 2025
- Published by Dnipro State Medical University in Medicni perspektivi
- Vol. 30 (3) , 68-81
Open AccessOxidative stress in skin diseases and the role of antioxidants in their treatment
More and more preclinical and clinical studies indicate the crucial role of oxidative stress in the pathogenesis of skin diseases. This became the basis for the analysis of current literature data on oxidative stress and antioxidant protection in the skin in the norm and dermatological diseases, as well as on the antioxidants use to manage this pathology.The aim of the study was to review the current literature on oxidative stress and antioxidant protection in the skin and to analyze the possibilities of using antioxidants in skin diseases. The search for literature sources for 2005-2025 was carried out in the biometric search engine PubMed using the terms: “oxidative stress”, “antioxidant”, “skin”, “skin disease”, “topical treatment”, “α-tocopherol”, “ascorbic acid”, “polyphenol”, “quercetin”, “coenzyme Q10”, “resveratrol”, “N-acetylcysteine”, as well as word combinations based on them. The inclusion criteria were: a document in English; publication in the period 2005-2025; compliance with search queries; availability of the article full text. The exclusion criteria were: a case from practice; conference proceedings; a publication that does not meet the purpose of the review; lack of full text, reflection of skin manifestations of a systemic disease or infection. The maximum number of literature sources was found for the query “oxidative stress – antioxidant – skin” (n=3076). After systematizing the selected documents using bibliographic and analytical methods, 115 of the most relevant sources remained. It was shown that the suppliers of reactive oxygen species (ROS) in the skin are processes that occur in keratinocytes, fibroblasts, and hematogenous cells. Many antioxidants eliminate ROS in the skin, they act together with superoxide dismutase, catalase, glutathione peroxidase and non-enzymatic antioxidants. Disruption of the balance between ROS and the power of antioxidant protection, i.e. oxidative stress, accompanies contact dermatitis, urticaria, atopic dermatitis, psoriasis, malignant skin tumors, photoaging, and vitiligo. The contribution of key natural antioxidants (ascorbic acid, α-tocopherol, retinoids, coenzyme Q10, resveratrol, selenium, and polyphenols) to skin care has been described, but there was only a small number of evidence-based studies that would justify the dosage and indications for their use in dermatology. Synthetic antioxidants are represented by almost one N-acetylcysteine in the treatment of toxic epidermal necrolysis, drug hypersensitivity syndrome, ichthyosis, contact and atopic dermatitis and some other diseases. The topical use of antioxidants is complicated by the search for an adequate dosage form, in which the stabilization of a substance with antioxidant properties is crucial, as well as its absorption, the ability to reach the target tissue in an active form and remain there for a long enough time, which is solved by the use of new methods of drug delivery, in particular based on nanotechnology. Thus, changes in the redox balance are widely represented in dermatoses, and the use of antioxidants can be of great importance if they are prescribed rationally. Obviously, it is advisable to combine antioxidants with each other and to introduce synthetic antioxidants more widely into practice.